Expression of FRS2 and FRS3 mRNA in clinical prostate cancer. A: Relative FRS2 and FRS3 mRNA expression in micro-dissected benign and tumours of different Gleason grades. Each profile represents a tumour derived from an individual patient. B. Relative alterations in FRS2 and FRS3 expression between benign and malignant prostate samples profiled in the MSKCC Prostate Oncogenome dataset (n = 131 tumours) (26). Here only a small minority of tumours had altered FRS2 and FRS3 mRNA with similar numbers exhibiting up-regulation or down-regulation of each.